| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.cian.co | |
| Market Cap | 60.36 Cr. | |
| Enterprise Value(EV) | 121.60 Cr. | 2022-03 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | -2.21 | Trailing Twelve Months Ending 2022-03 |
| Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2022-03 |
| Industry PE | 32.90 | Trailing Twelve Months Ending 2022-03 |
| Book Value / Share | 21.03 | Trailing Twelve Months Ending 2022-03 |
| Price to Book Value | 1.14 | Calculated using Price: 24.00 |
| Dividend Yield | 0.00 | Period Ending 2022-03 |
| No. of Shares Subscribed | 2.50 Cr. | 24,995,764 Shares |
| FaceValue | 10 | |
| Company Profile | ||
| The Company develops, manufactures and commercializes pharmaceutical products including sales, marketing, quality assurance, distribution, compliance and regulatory aspects under 12 therapeutic segments like Orthopaedics, Gynaecology, Paediatrics, Cardiac, Diabetic, Dermatology, Pain Management, Antibiotics, Neuro, Critical Care, Gastro-Intestinal and Nutraceuticals, along with 10 sales division focused on developing and growing its engagements in specialist and super specialist division. The company works under different business models like Brand Business, Export, Third Party Manufacturing and Government Supplies. The Company manufactures innovative products comprising of Tablets, Capsules, Liquid Orals, Ointments, Creams, Lotions, Gels and Sachet. The Company has special licence for manufacturing veterinary products for client like SAVAvet and Venky's. | ||
| 1 Day |
|
-4.95% |
| 1 Week |
|
+14.83% |
| 1 Month |
|
+29.73% |
| 3 Month |
|
+51.90% |
| 6 Month |
|
+60.0% |
| 1 Year |
|
-21.05% |
| 2 Year |
|
+95.92% |
| 5 Year |
|
|
| 10 Year |
|
| 3 years | 2020-03 | 2021-03 | 2022-03 | |
| Return on Equity (%) | -7.53 | 0.10 | -10.51 | |
| Return on Capital Employed (%) | 3.00 | 6.99 | 0.46 | |
| Return on Assets (%) | -2.42 | 0.03 | -3.42 |
| Particulars | 3 years | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
| Shh. Funds | 58 | 58 | 55 | |
| Non Curr. Liab. | 50 | 41 | 41 | |
| Curr. Liab. | 48 | 58 | 69 | |
| Minority Int. | ||||
| Equity & Liab. | 157 | 157 | 166 | |
| Non Curr. Assets | 94 | 88 | 84 | |
| Curr. Assets | 54 | 63 | 79 | |
| Misc. Exp. not W/O | 8 | 5 | 3 | |
| Total Assets | 157 | 157 | 166 |
| Particulars | 3 years | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
| Net Sales | 57 | 74 | 78 | |
| Other Income | 1 | 0 | 1 | |
| Total Income | 58 | 74 | 78 | |
| Total Expenditure | -50 | -62 | -74 | |
| PBIDT | 8 | 12 | 5 | |
| Interest | -7 | -8 | -7 | |
| Depreciation | -4 | -3 | -4 | |
| Taxation | 0 | -1 | 0 | |
| Exceptional Items | 0 | 0 | 0 | |
| PAT | -4 | 0 | -6 | |
| Minority Interest | ||||
| Share Associate | ||||
| Other Related Items | ||||
| Consolidated Net Profit | -4 | 0 | -6 | |
| Adjusted EPS | -2 | 0 | -2 |
| Particulars | 3 years | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
| Cash Fr. Operatn. | -7 | 6 | 9 | |
| Cash Fr. Inv. | -27 | 3 | 1 | |
| Cash Fr. Finan. | 36 | -10 | -11 | |
| Net Change | 1 | -1 | -1 | |
| Cash & Cash Eqvt | 3 | 2 | 1 |
|
Mon, 16 Jan 2023
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Certificate under Regulation 74 (5) OF SEBI (Depositories and Participants) Regulations 2018 for the Quarter ended 31st December 2022. |
|
Fri, 23 Dec 2022
REVISED SUBMISSION OF HALF YEARLY UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR ENDED 30TH SEPTEMBER 2022 AS PER REGULATION 33 OF SEBI (LODR) REGULATIONS 2015. REVISED SUBMISSION OF HALF YEARLY UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR ENDED 30TH SEPTEMBER 2022 AS PER REGULATION 33 OF SEBI (LODR) REGULATIONS 2015. |
|
Mon, 14 Nov 2022
SUBMISSION OF HALF YEARLY UNAUDITED FINANCIAL RESULTS OF CIAN HEALTHCARE LIMITED FOR THE HALF YEAR ENDED 30TH SEPTEMBER 2022 AS PER REGULATION 33 OF SEBI (LODR) REGULATIONS 2015. In pursuance of the SEBI (Listing Obligations & Disclosure Requirement) Regulations 2015 (Listing Regulations) please be informed that the Board of Directors at its meeting held on today i.e. Monday November 14 2022 to inter alia considered and approved the Un-Audited Financial Results (standalone and consolidated) for the quarter and half year ended September 30 2022 and took on record the Limited Review Report issued by the Statutory Auditors of the Company. |
| Fri, 27 Jan 2023 |
High Delivery Percentage
|
Opening at High
|
Closing Below Previous Low
|
Making Higher Highs for 3 days
|
Close Above Last Week High
|
Equities
M.F.
Sectors